Last spring, Rarity was awarded a grant from Swelife and Medtech4Health. The idea is to study superRCA for precision diagnostics and relapse detection for Acute Myeloid Leukemia and Myelodysplastic syndrome – ultimately improving treatment outcome, reducing patient burden and cost.
Part of the project aims to benchmark superRCA against ddPCR and investigate to what extent a more sensitive method would allow for peripheral blood samples to compliment and perhaps replace some bone marrow aspirates for minimal residual disease and relapse monitoring. This is a shared and motivating vision among the project parties that would drastically reduce patient burden and allow more frequent monitoring for early detection.
As part of a staged execution, a pilot cohort has been analyzed and the outcome strongly supports the project aim and study design. The project is now moving into the next phase.
“The collaboration within the project is going very well and the results are looking really exciting. We are all motivated and look forward to entering the next phase in the project!”Lucia Cavelier, Clinical Geneticist, Karolinska Institutet
The project is a partner project with Karolinska Institutet, SciLifeLabs and Uppsala University Hospital.
Swelife – For a competitive life science ecosystem in Sweden
Swelife is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners. Wesupport collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
Medtech4Health strive to increase the number and quality of new innovative products and services within medtech. In collaboration with patients, healthcare, academia and business, we contribute to increasing value for people affected by disease in their everyday lives. Medtech4Health is funded by the Swedish government through the innovation authority Vinnova and by the programme’s partners.